| Page | |
| EDITORIALS |
| 204 | How does one get around many of the confounding factors influencing the response to methacholine?
|
| 206 | Environmental plastics and lung health: Increasing evidence for concern
|
| 208 | Trajectories of lung function in urban firefighters
|
| 210 | “Safe air” to breathe: Time for action?
|
| 212 | PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease
|
| 215 | Variability in the response to atomoxetine and oxybutynin for OSA: Highlighting the need for personalized medicine
|
| 217 | Asthma and cardiovascular disease: A bidirectional association?
|
| COMMENTARIES |
| 220 | E-cigarette regulation: Is it time for a new Framework Convention on Tobacco Control?
Tanya Buchanan BA (Hons), Bsc (Nsg), MBA, PhD, Kylie Lindorff BASc, PGDip (Health Promotion), MPH, Kristin Carson-Chahhoud PhD, MSPPM, DipLabTech
10.1111/resp.14466 |
| 223 | Quantifying airway remodelling for research or clinical purposes: How should we normalize for airway size?
Graham M Donovan PhD, Kimberley C W Wang PhD, John G Elliot MSc, Alan L James MBBS, FRACP, MD, Peter B Noble PhD
10.1111/resp.14454 |
| ORIGINAL ARTICLES |
| Asthma and Allergy |
| 226 | The cumulative effect of methacholine on large and small airways when deep inspirations are avoided
Cyndi Henry, Magali Boucher, Marie-Ève Boulay, Andréanne Côté, Louis-Philippe Boulet, Ynuk Bossé
10.1111/resp.14387
The limited cumulative effect of serial doses of methacholine may be due to intercalated deep inspirations when the airway response is assessed by spirometry. In this study, oscillometry was used to avoid deep inspirations. The findings suggested that the effect of methacholine is cumulative on small but not large airways.
See related Editorial |
| Environmental and Occupational Lung Disease |
| 236 |
Longitudinal effects of prenatal exposure to plastic-derived chemicals and their metabolites on asthma and lung function from childhood into adulthood
Rachel E Foong, Peter Franklin, Francesca Sanna, Graham L Hall, Peter D Sly, Eric B Thorstensen, Dorota A Doherty, Jeffrey A Keelan, Roger J Hart
10.1111/resp.14386
This is the first study to show that prenatal exposure to plastic-derived chemicals and their metabolites may increase asthma risk and alter lung function from childhood into adulthood. These chemicals increased risk of asthma in males, but did not adversely affect lung function.
See related Editorial |
| 247 | Longitudinal lung function in urban firefighters: A group-based multi-trajectory modelling approach
Catherine Pendergrast, Terry Boyle, Alan J Crockett, Roger Eston, Kylie N Johnston
10.1111/resp.14382
It is unclear if urban firefighters involved in routine firefighting suffer from accelerated decline in lung function. This analysis identified three stable and two declining spirometry parameter z-score trajectory groups within the cohort. The declining trajectories were not associated with self-reported occupational characteristics of Years of Service and Respiratory Protection Use.
See related Editorial |
| Interstitial Lung Disease |
| 254 | Nitrogen dioxide increases the risk of disease progression in idiopathic pulmonary fibrosis
Hee-Young Yoon, Sun-Young Kim, Ok-Jin Kim, Jin Woo Song
10.1111/resp.14373
In a nationwide population-based study using estimated long-term personal air pollutant levels, an increase in NO2 level was associated with increased risk of disease progression of IPF in a model adjusted by individual- and area-level covariates. Our data suggest that avoiding exposure to NO2 might prevent disease progression in IPF.
See related Editorial |
| Pulmonary Vascular Disease |
| 262 | Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study
Timothy J W Dawes, Colm McCabe, Konstantinos Dimopoulos, Iain Stewart, Simon Bax, Carl Harries, Chinthaka B Samaranayake, Aleksander Kempny, Philip L Molyneaux, Samuel Seitler, Thomas Semple, Wei Li, Peter M George, Vasileios Kouranos, Felix Chua, Elisabetta A Renzoni, Maria Kokosi, Gisli Jenkins, Athol U Wells, Stephen J Wort, Laura C Price
10.1111/resp.14378
Retrospective cohort data from well phenotyped patients suggests that treatment with a phosphodiesterase 5 inhibitor (PDE5i) is associated with improved survival in patients with interstitial lung disease and severe pulmonary hypertension (ILD-PH), particularly in those with normal right ventricular function at presentation. A randomized controlled trial of pulmonary vasodilator therapy in ILD-PH is warranted.
See related Editorial |
| Sleep and Ventilation |
| 273 | Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial
Toru Kinouchi, Jiro Terada, Seiichiro Sakao, Ken Koshikawa, Tsuyoshi Sasaki, Atsuhiko Sugiyama, Shun Sato, Noriko Sakuma, Mitsuhiro Abe, Kohei Shikano, Nami Hayama, Yuki Shiko, Yoshihito Ozawa, Shinobu Ikeda, Takuji Suzuki, Koichiro Tatsumi
10.1111/resp.14383
Correction(s) for this article
10.1111/resp.14398
This study is a prospective clinical trial of atomoxetine and oxybutynin combination therapy in Japanese patients with obstructive sleep apnoea (OSA). Unlike previous reports, no significant improvement in OSA severity was observed, although a significant change in sleep architecture was detected, suggesting a different reactivity in Japanese OSA patients.
See related Editorial |
| FORUM AND DEBATE |
| Scientific Letter |
| 281 | Cardiovascular and cerebrovascular mortality in patients with preceding asthma exacerbation
|
| Personal Reflections |
| 287 | Every action matters, every bit of warming matters
|
| 289 | Transition towards the new normal
|
| 290 | Severe asthma, more than that?
|
| Letter from Asia-Pacific and Beyond |
| 291 | Letter from the Netherlands
|
| CORRIGENDUM |
| 294 | Corrigendum
10.1111/resp.14398 |
